Navigation Links
Human Genome Sciences Announces Second Quarter 2008 Financial Results and Key Developments
Date:7/30/2008

egulatory filings are expected in fall 2009. It is anticipated that a BLA will be filed in the United States in the first half of 2010. LymphoStat-B is being developed by HGS and GSK under a co-development and commercialization agreement entered into in August 2006.

At the 2008 Congress of the European League Against Rheumatism (EULAR) in June, the Company presented three-year data from a long-term Phase 2 continuation trial demonstrating that belimumab was associated with sustained improvement in disease activity across multiple clinical measures, decreased frequency of disease flares and potential steroid-sparing activity. It was also generally well tolerated through three years on treatment in combination with standard of care in patients with serologically active SLE. The results confirm and extend the data presented at previous scientific meetings at earlier time points, including a significant reduction in SLE disease activity as measured by the response rate chosen as the primary efficacy endpoint of the Phase 3 trials.

Oncology Products: Initial Data from HGS-ETR1 Multiple Myeloma Trial Expected Third Quarter 2008; Completion of Randomization in HGS-ETR1 NSCLC Trial Expected Shortly; HGS-ETR1 Hepatocellular Cancer Trial and First Clinical Trial of HGS1029 Initiated

Three randomized chemotherapy combination trials of HGS-ETR1 (mapatumumab) are currently underway to evaluate its potential in the treatment of specific cancers. Together, the three trials comprise a critical proof-of-concept phase in the development of HGS-ETR1:

-- HGS expects to have initial data available in the third quarter of 2008 from a randomized Phase 2 trial of HGS-ETR1 in combination with Velcade (bortezomib) in advanced multiple myeloma.

-- Enrollment is progressing well in the Company's randomized Phase 2 trial of HGS-ETR1 in combination with paclitaxel and carboplatin as first-line therapy in patients with non-small cell lung cancer (NSCLC). HGS now
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Human Genome Sciences Appoints David P. Southwell to its Board of Directors
2. Human Genome Sciences to Sponsor Conference Call to Discuss Second Quarter 2008 Financial Results
3. New map IDs the core of the human brain
4. BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use
5. Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
6. China Biologic Products Announces SFDA Approval for the Production and Sale of Human Albumin 12.5g/vial (25%, 50 ml)
7. MAP Pharmaceuticals Appoints Marco Rosa Vice President of Human Resources
8. Gen-Probe Launches in Europe CE-Marked APTIMA(R) HPV Assay for Detection of Human Papillomavirus
9. Robots moving closer to humans
10. Highest Replikin Concentrations and Cyclical Behavior Related to Human Mortality Are Found in Malaria Trypanosomes
11. Human Genome Sciences Names Kevin P. McRaith Vice President, Hepatology Franchise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Over the last decade, the laboratory ... R&D budgets and increased acceptance of new filtration technologies ... biotechnology industries are also catalyzing the growth of laboratory ... expected to grow at a strong CAGR during the ... worth $2,532.6 million by 2019. The market is mainly ...
(Date:9/30/2014)... California (PRWEB) September 30, 2014 ... the level of each type of cholesterol carrier or ... the presence of excessive cholesterol levels in the body, ... precursor condition to heart attack and other cardiovascular disorders. ... worldwide, therefore testing for cholesterol levels on a regular ...
(Date:9/30/2014)... -- CORD:USE Cord Blood Bank – www.corduse.com ... into an Equity and Exclusive Services Agreement with Tianhe Stem ... patented technologies for the isolation of human cord blood-derived ... performing Phase I/II clinical trials in China ... Tianhe,s Stem Cell Educator Therapy showing that the therapy ...
(Date:9/30/2014)... 2014 Genedata, a leading ... discovery and related life science research, today ... Genedata Selector as its host-pathogen data analysis ... is a European consortium dedicated to improving ... individualized anti-fungal drug therapies. Genedata Selector supports ...
Breaking Biology Technology:Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 4Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 5Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 3Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 4CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3
(Date:9/29/2014)... order to support the world,s needs to make ... more, new and more efficient catalytic materials and ... including several from Wayne State University, is tackling ... grant from the National Science Foundation. , The ... Multicomponent Materials for Electrocatalytic Cascade Reactions," was to ...
(Date:9/29/2014)... Scientists at Washington State University have concluded ... Smith apples may help prevent disorders associated ... first to assess these compounds in apple cultivars ... print edition of the journal Food Chemistry ... a good source of these nondigestible compounds but ...
(Date:9/29/2014)... presented Dr. Cristin Samper, president and CEO of ... of San Carlos. , The Order of San ... officers who have made outstanding contributions to the ... , An international authority on conservation biology and ... Colombian Residence in New York to receive the ...
Breaking Biology News(10 mins):Wayne State research aims to develop new, more efficient catalytic materials 2An apple a day could keep obesity away 2
... leukemia reversed symptoms of colitis in lab tests, according to ... Alberta. Faculty of Medicine & Dentistry researcher Shairaz Baksh ... ONE . His team discovered that a ... development of colitis. When this gene quits working or is ...
... medicines, enzymes for the food, cosmetics, and detergent industries: ... large scale using biotechnology. Currently, demand for biomolecules is ... or organisms. This involves researchers adding the gene that ... cultures of animal or plant cells. These modified organisms ...
... hosting a conference for researchers and clinicians on depression, ... Treatment Battlefeld and New Research," on Friday, November 1, ... Icahn School of Medicine at Mount Sinai, The Bonnie ... and 102nd Streets) in New York City. Recent meta-analyses ...
Cached Biology News:UAlberta medical researchers discover potential new treatment for colitis 2UAlberta medical researchers discover potential new treatment for colitis 3Biomolecules for the production line 2Biomolecules for the production line 3Towards a real understanding of depression 2